Targeting the molecular pathways underlying EndMT—including TGF-β signaling, oxidative stress response, and epigenetic regulation—may offer new therapeutic avenues to slow or reverse diabetes-induced cardiovascular deterioration. Here, TGFB1 is linked to diabetes mellitus.